|November 20, 2012||
Cancers as Systemic Functional Diseases, Part 2: Defining the Cancer Domain
Jeffrey Bland, PhD, FACN, FACB
The emerging view is that many cancers, due to present therapeutics, may become chronic diseases that need to be managed over many years with diet, lifestyle, and environment changes.1,2 Management of the patient that is appropriate for the stage of his or her disease is dependent upon the availability of biomarkers or screening tests that have been validated to define the status of the individual. Traditionally, four types of screening tests have been employed, including early-detection screening such as the Pap test, mammography, dermatology screen, oral screen, and colonoscopy. The second type of screening is the use of gene-based cellular tumor-specific markers such as KRAS, the APC gene, TP53 and BAT26 in stool sample DNA, or cytological examination of cells in sputum samples. The third type of screening test is the use of serum or urine genetic markers including cyclin E, MCM, PCNA, p16, BCL-2, and VEGF that monitor cell-cycle progression, DNA replication, DNA synthesis, cell-cycle control, antiapoptosis, and angiogenesis. One prime example of this is the use of CA-125 as a tumor marker for women with ovarian cancer. The fourth type of screening test employs soluble serum or urine metabolites to follow the course of disease such as the use of catecholamine metabolites such as vanillylmandelic acid (VMA) and homovanillic acid (HVA) in the urine of patients with neuroblastoma.